Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156976 | 1.00 | BRD4 (0.34) | BRD4 | |
| SCHEMBL4098576 | 1.00 | BRD4 (0.34) | BRD4 | |
| SCHEMBL9782530 | 0.86 | BRD4 (0.38) | BRD4 | |
| SCHEMBL10938403 | 0.86 | BRD4 (0.38) | BRD4 | |
| SCHEMBL10660255 | 0.84 | — | — | |
| SCHEMBL6963830 | 0.84 | — | — | |
| SCHEMBL6963835 | 0.84 | — | — | |
| SCHEMBL10415303 | 0.81 | ITGB1 (0.40) | — | |
| SCHEMBL11360693 | 0.81 | MT-CO2 (0.33) | — | |
| SCHEMBL9782696 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231322-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8440819-B2 | Therapeutic substituted beta-lactams | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090215740-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
| EP-1023265-B1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM CA LTD (CA) | 2003-01-15 | — | — | EP | disclosed |
| EP-1021405-B1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM CA LTD (CA) | 2002-09-25 | — | — | EP | disclosed |
| US-6242439-B1 | Azetidinone derivatives for the treatment of HCMV infections | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-06-05 | — | — | US | disclosed |
| US-6211170-B1 | Azetidinone derivatives for the treatment of HCMV infections | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231322-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | TUBB, GANAB, TUBB6 | BRD4 930/4885 |
| US-20090215740-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | TUBB, GANAB, TUBB6 | BRD4 930/4885 |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | VDR, CYP2R1, CYP24A1 | BRD4 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.